연구성과로 돌아가기

2020 연구성과별 연구자 정보 (911 / 2428)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Selleslag, Dominik Selleslag, D 3 AZ Sint Jan Brugge Oostende AV, Brugge, Belgium
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Montesinos, Pau Montesinos, P 4 Hosp Univ & Politecn La Fe, Valencia, Spain GYU-2673-2022 Montesinos, Pau 0000-0002-3275-5593 Montesinos, Pau
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Montesinos, Pau Montesinos, P 4 Inst Salud Carlos III, CIBERONC, Madrid, Spain GYU-2673-2022 Montesinos, Pau 0000-0002-3275-5593 Montesinos, Pau
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Sayar, Hamid Sayar, H 5 Indiana Univ, Ctr Canc, Indianapolis, IN USA
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Musso, Maurizio Musso, M 6 La Maddalena Casa Cura, Palermo, Italy
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Figuera Alvarez, Angela Alvarez, AF 7 Hosp Univ La Princesa, Madrid, Spain
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Safah, Hana Safah, H 8 Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Tse, William Tse, W 9 Univ Louisville, Sch Med, Louisville, KY 40292 USA
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Sohn, Sang Kyun Sohn, SK 10 Kyungpook Natl Univ Hosp, Daegu, South Korea
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Hiwase, Devendra Hiwase, D 11 Royal Adelaide Hosp, Adelaide, SA, Australia
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Chevassut, Timothy Chevassut, T 12 Brighton & Sussex Med Sch, Brighton, E Sussex, England
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Pierdomenico, Francesca Pierdomenico, F 13 Portuguese Inst Oncol Lisbon, Lisbon, Portugal
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial La Torre, Ignazia La Torre, I 14 Celgene, Boudry, Switzerland
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Skikne, Barry Skikne, B 15 Bristol Myers Squibb Co, Princeton, NJ USA
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial Skikne, Barry Skikne, B 15 Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
페이지 이동: